Investigational drug · Phase 3
PD-1 monoclonal antibody
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
1,502
Any phase or sponsor naming "PD-1 monoclonal antibody"
First trial start
2023
Nov 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PD-1 monoclonal antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nasopharyngeal Carcinoma (NPC)
- Non-small Cell Lung Cancer
- Nasopharyngeal Carcinoma
- Solid Tumor
- HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
- Triple-negative Breast Cancer
- Extensive-stage Small-cell Lung Cancer
- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PD-1 monoclonal antibody" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
Quanli GaoGovernment (non-federal)
NCT06693440 · 3,000 participants (planned) · Start Jul 1, 2021 · Primary completion Nov 13, 2027
Drug: PD-1 Inhibitors · For: Efficacy, Team; Adverse Event
Sites: Zhengzhou, China
Johns Hopkins UniversityAcademic, hospital or other
NCT04898751 · 2,214 participants · Start Jan 1, 2008 · Primary completion Aug 31, 2020
Drug: Immune checkpoint inhibitor (ICI) · For: Cutaneous Toxicity From ICI Therapy
Sites: Baltimore, Maryland
SWOG Cancer Research NetworkResearch network
NCT02154490 · 1,864 participants · Start Jul 8, 2014 · Primary completion Apr 1, 2022
Drug: Docetaxel; Durvalumab and 9 more · For: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,004 sites in all
CCTU- Cancer ThemeAcademic, hospital or other
NCT04107168 · 1,800 participants (planned) · Start Jul 8, 2020 · Primary completion Jul 8, 2024
Drug: Nivolumab; Pembrolizumab and 5 more · For: Melanoma; Renal Cancer; Lung Cancer
Sites: Bath, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 13 sites in all
- Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaPivotal-lookingRecruiting
Uppsala UniversityAcademic, hospital or other
NCT06488482 · 1,792 participants (planned) · Start Dec 19, 2024 · Primary completion Sep 2030
Drug: nivolumab or pembrolizumab · For: High-risk Melanoma
Sites: Helsinki, Finland; Kuopio, Finland; Tampere, Finland · 26 sites in all
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05608291 · 1,564 participants · Start Jan 16, 2023 · Primary completion Jan 15, 2027
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; San Francisco, California; Santa Monica, California · 211 sites in all
- An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01968109 · 1,482 participants · Start Nov 5, 2013 · Primary completion May 22, 2024
Drug: Relatlimab; Nivolumab and 1 more · For: Neoplasms by Site
Sites: La Jolla, California; Aurora, Colorado; Tampa, Florida · 54 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Optimization of PEI-mediated transient transfection for antibody production in Expi293F cells by iron ion supplementation.
Liu Y, Xiao S, Gui Y, et al. · Biochem Biophys Rep 2026
- An Ii-Key-containing HPV16/18 E7 epitope peptide vaccine promotes dendritic cell activation and T-cell immunity in a murine HPV16 tumor model, with greater tumor control upon PD-1 blockade.
Li Z, Shen L, Wang X, et al. · Int Immunopharmacol 2026
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.
Ghelardi F, Ambrosini M, Raimondi A, et al. · Nat Med 2026
- Role of CircRNA_0005075 in gastric cancer immune evasion through regulation of lactate metabolic reprogramming and histone lactylation.
Wu J, Jiang J, Chen C, et al. · Transl Oncol 2026
- Complement C5a Fosters Tumor-promoting Immunity by Recruiting regulatory T cells in hepatocellular carcinoma.
Huang R, Chu T, Zhu G, et al. · Cancer Lett 2026
- Pharmacokinetics and safety of an engineered anti-feline PD-1 chimeric antibody following repeated intravenous and subcutaneous administration in healthy cats.
Nishibori S, Shiga T, Tsukui T, et al. · Vet Immunol Immunopathol 2026
Also in development for Nasopharyngeal Carcinoma (NPC)
- BL-M08D1Phase 26 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.